These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 24749839)
81. Hairy cell leukemia: 2020 update on diagnosis, risk stratification, and treatment. Maitre E; Cornet E; Troussard X Am J Hematol; 2019 Dec; 94(12):1413-1422. PubMed ID: 31591741 [TBL] [Abstract][Full Text] [Related]
82. Second Neoplasms in Italian Patients with Hairy Cell Leukemia after Treatment with Cladribine: A Multicenter Investigation and Literature Review. Criscuolo M; Tosti ME; Broccoli A; Varettoni M; Maraglino AME; Anastasia A; Cantonetti M; Trentin L; Kovalchuk S; Orsucci L; Deodato M; Spolzino A; Volpetti S; Annibali O; Storti S; Stelitano C; Marchesi F; Morè S; Fianchi L; Falini B; Pulsoni A; Tiacci E; Zinzani PL; Pagano L Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672557 [TBL] [Abstract][Full Text] [Related]
83. [Chinese guideline for diagnosis and treatment of hairy cell leukemia (2023)]. ; ; Zhonghua Xue Ye Xue Za Zhi; 2023 Dec; 44(12):969-976. PubMed ID: 38503518 [No Abstract] [Full Text] [Related]
84. Atypical meningeal localization of classical hairy cell leukemia with an impressive response to rituximab and cladribine association. A case report and literature review. Claves F; Carras S; Burroni B; Maitre E; Boutonnat J; Troussard X; Molina L EJHaem; 2024 Feb; 5(1):242-246. PubMed ID: 38406549 [TBL] [Abstract][Full Text] [Related]
85. Single-agent rituximab is an effective salvage therapy in pretreated patients with hairy cell leukemia. Broccoli A; Argnani L; Nanni L; Stefoni V; Pellegrini C; Casadei B; Gugliotta G; Carella M; Coppola PE; Bagnato G; Zinzani PL Blood Adv; 2023 Nov; 7(21):6762-6766. PubMed ID: 37738174 [No Abstract] [Full Text] [Related]
86. Remarkable Response of Hairy Cell Leukemia Variant to Single-Agent Cladribine. Otieno SB; Ogbeide O Cureus; 2022 May; 14(5):e24976. PubMed ID: 35698717 [TBL] [Abstract][Full Text] [Related]
87. A 3-decade multicenter European experience with cladribine as upfront treatment in 384 patients with hairy cell leukemia. Broccoli A; Argnani L; Cross M; Janus A; Maitre E; Troussard X; Robak T; Dearden C; Else M; Catovsky D; Zinzani PL Blood Adv; 2022 Jul; 6(14):4224-4227. PubMed ID: 35584397 [TBL] [Abstract][Full Text] [Related]
88. Case Report: Development of Diffuse Large B Cell Lymphoma a Long Time After Hairy Cell Leukemia. Nagy ZF; Ferenczi K; Istenes I; Eid H; Bödör C; Timár B; Demeter J Pathol Oncol Res; 2022; 28():1610338. PubMed ID: 35570843 [TBL] [Abstract][Full Text] [Related]
89. Updates in hairy cell leukemia (HCL) and variant-type HCL (HCL-V): rationale for targeted treatments with a focus on ibrutinib. Paillassa J; Safa F; Troussard X Ther Adv Hematol; 2022; 13():20406207221090886. PubMed ID: 35450208 [TBL] [Abstract][Full Text] [Related]
90. How to Diagnose and Treat CD5-Positive Lymphomas Involving the Spleen. Cabeçadas J; Nava VE; Ascensao JL; Gomes da Silva M Curr Oncol; 2021 Nov; 28(6):4611-4633. PubMed ID: 34898558 [TBL] [Abstract][Full Text] [Related]
91. Patients with relapsed/refractory hairy-cell leukemia. Paillassa J; Troussard X Cancer Rep (Hoboken); 2022 Mar; 5(3):e1495. PubMed ID: 34250762 [TBL] [Abstract][Full Text] [Related]
92. Analysis of a cohort of 279 patients with hairy-cell leukemia (HCL): 10 years of follow-up. Paillassa J; Cornet E; Noel S; Tomowiak C; Lepretre S; Vaudaux S; Dupuis J; Devidas A; Joly B; Petitdidier-Lionnet C; Haiat S; Mariette C; Thieblemont C; Decaudin D; Validire-Charpy P; Drenou B; Eisenmann JC; Uribe MO; Olivrie A; Touati M; Lambotte O; Hermine O; Karsenti JM; Feugier P; Vaillant W; Gutnecht J; Lippert E; Huysman F; Ghomari K; Boubaya M; Levy V; Riou J; Damaj G; Tanguy-Schmidt A; Hunault-Berger M; Troussard X Blood Cancer J; 2020 May; 10(5):62. PubMed ID: 32461544 [TBL] [Abstract][Full Text] [Related]